BIOMAT Database Logo BIOMAT Database Logo

Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. 1998

T Shibusa, and N Shijubo, and S Abe
Third Department of Internal Medicine, Sapporo Medical University School of Medicine, Japan.

Vascular endothelial growth factor (VEGF) is one of the most important factors for angiogenesis in various malignant tumors. However, the biological significance of VEGF in lung adenocarcinoma remains unclear. We stained intratumoral microvessels immunohistochemically using anti-CD34 antibody and analyzed VEGF expression using anti-VEGF antibody in 44 cases of stage I lung adenocarcinoma. Of the 44 patients studied, 14 patients had a postoperative relapse, and 30 patients did not. The mean microvessel count (MVC) in stage I lung adenocarcinoma was 79.5 +/- 26.9 per x200 microscopic field. Immunohistochemical expression of VEGF was found in 27 of 44 cases of stage I lung adenocarcinoma. The mean MVC in cases of VEGF-positive lung adenocarcinoma (86.4 +/- 28.2) was significantly higher than that in cases of VEGF-negative lung adenocarcinoma (68.6 +/- 21.4; P < 0.05). The high-MVC group patients (MVC > 80) had significantly worse survival rates than those in the low-MVC group (MVC < or = 80; P < 0.01), and patients with VEGF-negative tumors had significantly better survival rates than those with VEGF-positive tumors (P < 0.05). We conclude that angiogenesis, as assessed by intratumoral MVCs, is a significant prognostic factor in stage I lung adenocarcinoma, and that VEGF is an important angiogenic factor in stage I lung adenocarcinoma.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008222 Lymphokines Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity. Lymphocyte Mediators,Mediators, Lymphocyte
D008297 Male Males
D008833 Microcirculation The circulation of the BLOOD through the MICROVASCULAR NETWORK. Microvascular Blood Flow,Microvascular Circulation,Blood Flow, Microvascular,Circulation, Microvascular,Flow, Microvascular Blood,Microvascular Blood Flows,Microvascular Circulations
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D009389 Neovascularization, Pathologic A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions. Angiogenesis, Pathologic,Angiogenesis, Pathological,Neovascularization, Pathological,Pathologic Angiogenesis,Pathologic Neovascularization,Pathological Angiogenesis,Pathological Neovascularization
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Shibusa, and N Shijubo, and S Abe
Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma.
October 1999, American journal of respiratory and critical care medicine,
T Shibusa, and N Shijubo, and S Abe
Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma.
February 2002, Cancer,
T Shibusa, and N Shijubo, and S Abe
Tumor angiogenesis as a major prognostic factor in stage I lung adenocarcinoma.
January 1997, Anticancer research,
T Shibusa, and N Shijubo, and S Abe
Celecoxib can induce vascular endothelial growth factor expression and tumor angiogenesis.
January 2011, Molecular cancer therapeutics,
T Shibusa, and N Shijubo, and S Abe
Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression.
March 1999, Journal of the National Cancer Institute,
T Shibusa, and N Shijubo, and S Abe
Vascular endothelial growth-factor expression and angiogenesis in nonsmall cell lung carcinomas.
May 1995, International journal of oncology,
T Shibusa, and N Shijubo, and S Abe
Association between vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in ameloblastomas.
January 2002, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology,
T Shibusa, and N Shijubo, and S Abe
[Association of vascular endothelial growth factor expression with angiogenesis and tumor cell proliferation in human lung cancer].
January 2001, Zhonghua nei ke za zhi,
T Shibusa, and N Shijubo, and S Abe
Tumor angiogenesis, apoptosis, and p53 oncogene in stage I lung adenocarcinoma.
January 1999, Surgery today,
T Shibusa, and N Shijubo, and S Abe
Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia.
August 1995, Journal of the National Cancer Institute,
Copied contents to your clipboard!